Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis : Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Show full item record



Permalink

http://hdl.handle.net/10138/313696

Citation

Raj , K , Eikema , D-J , McLornanl , D P , Olavarria , E , Bloke , H-J , Bregante , S , Ciceri , F , Passweg , J , Ljungman , P , Schaap , N , Carlson , K , Zuckerman , T , de Wreede , L C , Volin , L , Koc , Y , Luis Diez-Martin , J , Brossart , P , Wolf , D , Blaise , D , Di Bartolomeo , P , Vitek , A , Robin , M , Yakoub-Agha , I , Chalandon , Y & Kroger , N 2019 , ' Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis : Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation ' , Biology of Blood and Marrow Transplantation , vol. 25 , no. 3 , pp. 522-528 . https://doi.org/10.1016/j.bbmt.2018.10.017

Title: Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis : Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Author: Raj, Kavita; Eikema, Diderik-Jan; McLornanl, Donal P.; Olavarria, Eduardo; Bloke, Henric-Jan; Bregante, Stefania; Ciceri, Fabio; Passweg, Jakob; Ljungman, Per; Schaap, Nicolaas; Carlson, Kristina; Zuckerman, Tsila; de Wreede, Liesbeth C.; Volin, Liisa; Koc, Yener; Luis Diez-Martin, Jose; Brossart, Peter; Wolf, Dominik; Blaise, Didier; Di Bartolomeo, Paolo; Vitek, Antonin; Robin, Marie; Yakoub-Agha, Ibrahim; Chalandon, Yves; Kroger, Nicolaus
Contributor: University of Helsinki, Clinicum
Date: 2019-03
Language: eng
Number of pages: 7
Belongs to series: Biology of Blood and Marrow Transplantation
ISSN: 1083-8791
URI: http://hdl.handle.net/10138/313696
Abstract: This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34(+) cell dose was 4.8 x 10(6)/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28 days was 82% (range, 70% to 93%), at a median of 21 days (range, 19 to 23). At 2 years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and Ill to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100 days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% 95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion. (C) 2018 American Society for Blood and Marrow Transplantation.
Subject: Myelofibrosis
Haploidentical
Mismatched related donor
UMBILICAL-CORD BLOOD
HEMATOLOGIC MALIGNANCIES
POLYCYTHEMIA-VERA
CYCLOPHOSPHAMIDE
ENGRAFTMENT
LEUKEMIA
3121 General medicine, internal medicine and other clinical medicine
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Family_mismatch ... _Working_Party_of_EBMT.pdf 1.310Mb PDF View/Open
1_s2.0_S1083879118306505_main.pdf 589.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record